Lu177 Treatments

Isotopia currently provides two main Theranostic products: 177Lu DOTATATE and 177Lu PSMA I&T.

Prostate-Specific Membrane Antigen (PSMA) Therapy is becoming a popular treatment choice for men experiencing advanced prostate cancer with metastatic or treatment-resistant prostate tumors. Lu177 PSMA I&T is an extensively investigated PSMA radioligand for Radionuclide Therapy (RLT) utilizing the Theranostic concept that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment followed by a SPECT scan after 24-72 hours to ensure disease sites have been adequately targeted.


For non GEP-NET treatments

*For the domestic market
Our main goal is to provide this breakthrough treatment to every patient in the state of Israel who meets the eligibility criteria.

I want more details please